Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulation

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1327-1336

  Marushima, Hideki ^a   Shibata, Shun Ichi ^a   Asakura, Tadashi ^a   Matsuura, Tomokazu ^a   Maehashi, Haruka ^a   Ishii, Yuji ^a   Eda, Homare ^a   Aoki, Katsuhiko ^a   Iida, Yasushi ^a   Morikawa, Toshiaki ^a   Ohkawa, Kiyoshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

3D cell culture; DNA array; Hypoxia; TGF

Indexed keywords

CARBONATE DEHYDRATASE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 8; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL 4 HYDROXYLASE 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANAEROBIC METABOLISM; ANIMAL EXPERIMENT; ARTICLE; BIOREACTOR; CANCER CELL CULTURE; CARCINOMA CELL; CELL DENSITY; CELL HYPOXIA; CELL STRUCTURE; ENERGY METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; RADIAL FLOW BIOREACTOR; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, NUDE; SPHEROIDS, CELLULAR; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053176453     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1142     Document Type: Article

References (80)

1. Nguyen DX and Massagué J: Genetic determinants of cancer metastasis. Nat Rev Genet 8: 341-352, 2007. (Pubitemid 46625811)
2. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005. (Pubitemid 41267170)
3. Tarin D, Thompson EW and Newgreen DF: The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65: 5996-6000, 2005. (Pubitemid 40994379)
4. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK and Alitalo K: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423-1425, 1997. (Pubitemid 27235412)
5. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 40: 177-184, 1988.
6. Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998. (Pubitemid 28193601)
7. Tomida A and Tsuruo T: Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 14: 169-177, 1999. (Pubitemid 29292313)
8. Gupta GP and Massagué J: Cancer metastasis: building a framework. Cell 17: 679-695, 2006. (Pubitemid 44781029)
9. Gogvadze V, Orrenius S and Zhivotovsky B: Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18: 165-173, 2008.
10. Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008. (Pubitemid 351766797)
11. Semenza GL: Tumor metabolism: cancer cells give and take lactate. J Clin Invest 118: 3835-3837, 2008.
12. Margulis A, Zhang W, Alt-Holland A, Crawford HC, Fusenig NE and Garlick JA: E-cadherin suppression accelerates squamous cell carcinoma progression in th170 ree-dimensional, human tissue constructs. Cancer Res 65: 1783-1791, 2005. (Pubitemid 40478605)
13. Debnath J and Brugge JS: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5: 675-688, 2005. (Pubitemid 41486361)
14. Friedrich MJ: Studying cancer in 3 dimensions. 3-D models foster new insights into tumorigenesis. JAMA 18: 1977-1979, 2007.
15. Muthuswamy SK, Li D, Lelievre S, Bissell MJ and Brugge JS: ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3: 785-792, 2001. (Pubitemid 32842683)
16. Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, Heberer M and Reschner A: Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 204: 522-531, 2005. (Pubitemid 40934647)
17. Hongo T, Kajikawa M, Ishida S, Ozawa S, Ohno Y, Sawada J, Ishikawa Y and Honda H: Gene expression property of high-density three-dimensional tissue of HepG2 cells formed in radial-flow bioreactor. J Biosci Bioeng 101: 243-250, 2006. (Pubitemid 44354394)
18. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK and Brugge JS: The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40, 2002.
19. Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z and Bissell MJ: Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205-216, 2002. (Pubitemid 41043976)
20. Shibata S, Marushima H, Asakura T, Matsuura T, Eda H, Aoki K, Matsudaira H, Ueda K and Ohkawa K: Three-dimensional culture using a radial flow bioreactor induces matrix metalloprotease 7-mediated EMT-like process in tumor cells via TGFbeta1/Smad pathway. Int J Oncol 34: 1433-1448, 2009.
21. Choi KS, Bae MK, Jeong JW, Moon HE and Kim KW: Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 36: 120-127, 2003.
22. Ke Q and Costa M: Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70: 1469-1480, 2006.
23. De Clerck K and Elble RC: The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci 15: 213-225, 2010.
24. Mizukami Y, Kohgo Y and Chung DC: Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 13: 5670-5674, 2007. (Pubitemid 47583891)
25. Calzada MJ and Del Peso L: Hypoxia-inducible factors and cancer. Clin Transl Oncol 9: 278-289, 2007.
26. Sahlgren C, Gustafsson MV, Jin S, Poellinger L and Lendahl U: Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105: 6392-6397, 2008. (Pubitemid 351758356)
27. Liao D and Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26: 281-290, 2007. (Pubitemid 47101669)
28. Chaudary N and Hill RP: Hypoxia and metastasis in breast cancer. Breast Dis 26: 55-64, 2007.
29. Bristow RG and Hill RP: Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180-192, 2008. (Pubitemid 351301853)
30. Semenza GL: Hypoxia-inducible factor 1: regulator of mito-chondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta doi:10.1016/j.bbamcr.2010.08.006, 2010.
31. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
32. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
33. Semenza GL: HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56, 2010.
34. Semenza GL: Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology 24: 97-106, 2009.
35. Semenza GL: Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16, 2009.
36. Aizaki H, Nagamori S, Matsuda M, Kawakami H, Hashimoto O, Ishiko H, Kawada M, Matsuura T, Hasumura S, Matsuura Y, Suzuki T and Miyamura T: Production and release of infectious hepatitis C virus from human liver cell cultures in the three-dimensional radial-flow bioreactor. Virology 15: 16-25, 2003. (Pubitemid 37153297)
37. Kanai H, Marushima H, Kimura N, Iwaki T, Saito M, Maehashi H, Shimizu K, Muto M, Masaki T, Ohkawa K, Yokoyama K, Nakayama M, Harada T, Hano H, Hataba Y, Fukuda T, Nakamura M, Totsuka N, Ishikawa S, Unemura Y, Ishii Y, Yanaga K and Matsuura T: Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopat. Artif Organs 31: 148-151, 2007.
38. Ohkawa K, Hatano T, Yamada K, Joh K, Takada K, Tsukada Y and Matsuda M: Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 53: 4238-4242, 1993. (Pubitemid 24146772)
39. Ohkawa K, Amasaki H, Terashima Y, Aizawa S and Ishikawa E: Clear cell carcinoma of the ovary, light and electron microscopic studies. Cancer 40: 3019-3029, 1977.
40. Gaedtke L, Thoenes L, Culmsee C, Mayer B and Wagner E: Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. J Proteome Res 6: 4111-4118, 2007. (Pubitemid 350158489)
41. Morales J and Alpaugh ML: Gain in cellular organization of inflammatory breast cancer: a 3D in vitro model that mimics the in vivo metastasis. BMC Cancer 9: 462, 2009.
42. Candi E, Tarcsa E, Idler WW, Kartasova T, Marekov LN and Steinert PM: Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins. integration with loricrin. J Biol Chem 274: 7226-7237, 1999.
43. Feron O: Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92: 329-333, 2009.
44. Pouysségur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443, 2006. (Pubitemid 44050138)
45. Semenza GL: Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007: cm8, 2007.
46. Kim JW, Tchernyshyov I, Semenza GL and Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185, 2006.
47. Papandreou RA, Cairns L, Fontana AL, Lim and Denko NC: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187-197, 2006.
48. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O and Dewhirst MW: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118: 3930-3942, 2008.
49. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ and Semenza GL: Mitochondrial autophagy is a HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283: 10892-10903, 2008.
50. Ullah MS, Davies AJ and Halestrap AP: The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281: 9030-9037, 2006. (Pubitemid 43864615)
51. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K and Johnson RS: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 21: 3436-3444, 2001. (Pubitemid 32381779)
52. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P and Metzen E: Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J 381: 761-767, 2004. (Pubitemid 39120486)
53. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D and Pouysségur J: HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090, 2003. (Pubitemid 37021737)
54. Barth S, Nesper J, Hasgall PA, Wirthner R, Nytko KJ, Edlich F, Katschinski DM, Stiehl DP, Wenger RH and Camenisch G: The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 27: 3758-3768, 2007. (Pubitemid 46726183)
55. Barth S, Edlich F, Berchner-Pfannschmidt U, Gneuss S, Jahreis G, Hasgall PA, Fandrey J, Wenger RH and Camenisch G: Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance depends on integral membrane anchoring of FKBP38. J Biol Chem 284: 23046-23058, 2009.
56. Metzen E, Stiehl DP, Doege K, Marxsen JH, Hellwig-Bürgel T and Jelkmann W: Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 387: 711-717, 2005. (Pubitemid 40685705)
57. Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB, Bowtell DD and Ronai Z: Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 117: 941-952, 2004. (Pubitemid 38798859)
58. Pescador N, Cuevas Y, Naranjo S, Alcaide M, Villar D, Landázuri MO and Del Peso L: Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J 390: 189-197, 2005. (Pubitemid 41192244)
59. Stiehl DP, Wirthner R, Köditz J, Spielmann P, Camenisch G and Wenger RH: Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an auto-regulatory oxygen-sensing system. J Biol Chem 281: 23482-23491, 2006. (Pubitemid 44274123)
60. Pistollato F, Rampazzo E, Abbadi S, Della Puppa A, Scienza R, D'Avella D, Denaro L, Te Kronnie G, Panchision DM and Basso G: Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells. PLoS One 4: e6206, 2009.
61. Kong X, Lin Z, Liang D, Fath D, Sang N and Caro J: Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019-2028, 2006. (Pubitemid 43346906)
62. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F and Neckers LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944, 2002.
63. De Simone G and Supuran CT: Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 1804: 404-409, 2010.
64. Swietach P, Patiar S, Supuran CT, Harris AL and Vaughan-Jones RD: The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem 284: 20299-20310, 2009.
65. Thiry A, Dogné JM, Masereel B and Supuran CT: Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 27: 566-573, 2006. (Pubitemid 44574507)
66. Supuran CT: Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In: Carbonic Anhydrase. Its Inhibitors and Activators. Supuran CT, et al (eds). CRC Press, pp1-23, 2004.
67. Wykoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW and Ratcliffe PJ: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083, 2000. (Pubitemid 32059187)
68. Pastoreková S and Pastorek J: Cancer-related carbonic anhydrase isozymes and their inhibition. In: Carbonic Anhydrase. Its Inhibitors and Activators. Supuran CT, et al (eds). CRC Press, pp255-281, 2004.
69. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI and Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-919, 2001. (Pubitemid 32221783)
70. Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001. (Pubitemid 32219813)
71. Pastorekova S, Parkkila S, Pastorek J and Supuran CT: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 19: 199-229, 2004. (Pubitemid 39004275)
72. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL and Fox SB: Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12: 4562-4568, 2006. (Pubitemid 44297805)
73. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R and Nuyts S: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 5: 42, 2005.
74. Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ and Stanbridge EJ: Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 116: 452-458, 2010.
75. Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K and Mahner S: Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. Gynecol Oncol 117: 183-188, 2010.
76. Hyrsl L, Zavada J, Zavadova Z, Kawaciuk I, Vesely S and Skapa P: Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma 56: 298-302 2009.
77. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O'Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, Harris AL and Fox SB: The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100: 405-411, 2009.
78. Pastorek J, Pastoreková S, Callebaut I, Mornon JP, Zelník V, Opavský R, Zat'ovicová M, Liao S, Portetelle D, Stanbridge EJ, et al: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9: 2877-2888, 1994.
79. Kaluz S, Kaluzová M, Chrastina A, Olive PL, Pastoreková S, Pastorek J, Lerman MI and Stanbridge EJ: Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 62: 4469-4477, 2002. (Pubitemid 34827310)
80. Sussman NL, Chong MG, Koussayer T, He DE, Shang TA, Whisennand HH and Kelly JH: Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 16: 60-65, 1992.